EVERSANA

Overview

EVERSANA is the largest integrated pharmaceutical commercialization services provider, offering an end-to-end platform that spans from strategic advisory through field sales, patient services, specialty pharmacy, and data analytics. Founded in 2018 through a series of acquisitions and platform-building by the Slessor family and backed by private equity, EVERSANA has rapidly assembled a uniquely broad capability set. The company serves 25 of the top 25 bio-pharmaceutical firms and more than 670 bio-pharmaceutical and device customers across large pharma, emerging biotech, devices/diagnostics, and nutrition/wellness.

EVERSANA’s strategic thesis is that fragmented vendor ecosystems (separate hub vendor, copay provider, specialty pharmacy, field force, agency) create data silos and coordination failures that cause drug launches to miss forecast. Their integrated model claims to solve this by providing a single platform with end-to-end data visibility across the entire commercialization lifecycle.

The company was notably valued at approximately $975M (21.3x EBITDA) when it acquired InTouch Group in October 2021, giving context to its scale among pharma services companies.

Services & Capabilities

Patient Services & Hub (Core)

Comprehensive access and reimbursement support:

• Access & Enrollment: End-to-end access and reimbursement solutions enhanced by EHR connectivity
• Benefit Verification: Proprietary ACTICS eAccess platform with direct connectivity to 1,400+ payers covering 90% of U.S. covered lives. eBV success rate of 90% (vs. 43% industry average). Real-time results for both pharmacy and major medical benefits.
• Electronic Prior Authorization (ePA): Proprietary PA criteria repository pre-populates medical necessity information; 92-96% of ePAs accepted as complete (vs. 73% industry rejection rate). Real-time notifications and status tracking.
• Patient Navigator model: Dedicated case managers as single point of contact with concierge support
• Automated tools: OCR data intake automation, call bots for payer interactions, chatbot (compliant conversational AI, web/mobile/SMS compatible)
• Operations: 5% staffing bench for surge capacity, extensive training and development, robust quality monitoring, evidence-based continuous improvement

Affordability Solutions

• Copay programs: Omni-channel enrollment (EHR, digital concierge, brand website via open APIs, portals, IVR, hub integration, mobile/SMS/QR code)
• Advanced adjudication: MedxClaim (HCP-administered), debit/alternative payment vehicles, digital claim submissions, ProXeclaim
• Patient Assistance Programs (PAP): Automated intake via Business Rules Engine, electronic income validation (99% accuracy), alternate funding source screening
• Digital wallet savings cards: Text-to-activate with mobile wallet integration; ~20% of patients use this distribution method
• Analytics: Accumulator detection, fraud/waste/abuse monitoring, adherence tracking, program optimization

Specialty Pharmacy (Owned)

Operated from Chesterfield, Missouri facility:

• 11,200 sq. ft. temperature-validated dispensing/distribution space
• 85,000+ shipments processed annually; capacity for 10M+ TRx
• 99% dispensing accuracy, 99.8% inventory accuracy, 98% on-time shipments, 99% network coverage
• Ships to all 50 states, Puerto Rico, and U.S. territories
• Distinct commercial and non-commercial dispensing pharmacies
• Dual pharmacist verification (PV1 + PV2) with automated Icon machine
• Handles PAP and bridge free drug programs
• Therapeutic expertise: MS, immunology, dermatology, cardiovascular, respiratory, oncology, cell and gene therapy

In-Home Nursing & Clinical Support

• Nationwide in-home nursing network
• Telephonic clinical nurse navigators for self-injection support
• Cisco VoIP telephony with IVR, ACD, call recording, quality assurance (Calabrio)
• High-touch patient engagement and behavioral medication via live coaching

Direct-to-Patient (DTP) / Telehealth

Powered by partnership with Upscript Health:

• End-to-end virtual care model: patient targeting, digital engagement, virtual HCP consult, ePrescribing, benefit verification, pharmacy dispensing, adherence support
• Claims to be the “industry’s first and only patient-led virtual care model”
• Case study: Chronic condition brand generating 90K+ prescriptions shipped annually; telehealth generating 20% of overall brand revenue; Patient NPS of 74
• ML-powered telehealth propensity scoring for patient identification

Field Deployment Solutions

• Contract sales forces (traditional rep model)
• Medical science liaisons (MSLs)
• Field reimbursement managers (FRMs)
• Nurse educators

Agency Solutions

• Creative, branding, omnichannel marketing
• EVERSANA ORCHESTRATE: omnichannel engagement platform connecting HCP and patient touchpoints
• Digital Concierge: AI and/or live chat via web and SMS with eBV/ePA integration

Advisory Services & Market Access

• Strategic consulting on commercialization
• Payer strategy and formulary positioning
• Pricing strategy and HEOR
• Medical affairs and publication planning

Trade, Channel & 3PL

• Distribution and logistics services
• Channel management

Competitive Position

EVERSANA occupies a unique position as the most broadly integrated commercialization partner in pharma services. Key differentiators:

1. Breadth of integration: No other single provider combines advisory, field force, agency, patient services, specialty pharmacy, market access, and data analytics
2. Owned specialty pharmacy: Eliminates the hub-to-pharmacy handoff gap that limits independent hub providers (like ConnectiveRx)
3. ACTICS data platform: 280M+ lives with ML/AI for patient finding, propensity modeling, and campaign optimization; longitudinal linkage across claims, EHR, affiliations, formulary data
4. DTP/telehealth capability: First-mover in pharma-branded virtual care; creating a new patient acquisition channel beyond traditional HCP-pharmacy pathways
5. eAccess technology: 90% eBV success rate and 92-96% ePA acceptance rate significantly outperform industry averages

Key limitations:

• Breadth may come at the expense of depth in any single service line
• Large pharma companies with established vendor relationships may prefer best-of-breed point solutions for leverage and specialization
• Integrated model requires clients to trust a single vendor across critical functions
• Younger company (founded 2018) with less track record than established point-solution providers

Market context: ConnectiveRx (pure-play hub/copay/A&A) was identified as a leading independent competitor in its PE diligence materials. The competitive dynamic between integrated players like EVERSANA and independent specialists like ConnectiveRx is the central strategic tension in the hub services market.

Recent Developments

• October 2021: Acquired InTouch Group for approximately $975M (21.3x EBITDA), adding agency and omnichannel capabilities
• 2023-2024: Launched EVERSANA ORCHESTRATE omnichannel platform
• 2024: Published updated Patient Services capabilities deck reflecting expanded DTP/telehealth offering via Upscript Health partnership
• Ongoing: Continued platform integration across acquired entities

Client & Partner Ecosystem

• Serves 25 of the top 25 bio-pharmaceutical firms
• 670+ bio-pharmaceutical and device customers
• Customer segments: large pharma, emerging biotech, devices & diagnostics, nutrition & wellness
• Key technology partnership: Upscript Health (telehealth platform)
• Cisco (telephony infrastructure), Calabrio (quality assurance)
• 35+ patient services customers specifically

Technology Platform

• ACTICS by EVERSANA: Proprietary data and analytics platform linking 300M U.S. patient records across Rx claims, EHR data, affiliations, formulary/policy data, SP & hub data, CMS open payments. Provides ML-powered patient identification, switch prediction, telehealth propensity scoring, and provider segmentation.
• ACTICS eAccess: Real-time eBV/ePA platform with API integration into Brand.com, CRM, or portals. Direct connectivity to 1,400+ payers covering 90% of U.S. covered lives.
• EVERSANA ORCHESTRATE: Omnichannel engagement engine connecting field force, digital, patient services, and HCP touchpoints. Modular platform “in a box” powered by AI.
• Digital Concierge: AI and/or live chat solution with eBV/ePA integration, pharmacy selection, copay offer/wallet, and SMS reminders.
• Chatbot: Compliant conversational AI engine, web/mobile/SMS compatible, embeddable on websites or triggered via QR codes.
• CRM Platform: Supports hub case management, patient engagement plans, and operational dashboards with individual/team productivity tracking.

Therapeutic Focus

Broad coverage with specialty pharmacy expertise in:

• Multiple sclerosis
• Immunology
• Dermatology
• Cardiovascular
• Respiratory
• Oncology
• Cell and gene therapy

Target Customers

• Large pharma: Enterprise-level relationships leveraging the full integrated platform
• Emerging biotech: Full-scale launch support (single vendor for all commercialization needs)
• Established brands: Revenue revitalization and lifecycle management
• Devices & diagnostics: Expanded from core pharma focus
• Specific use cases: Products requiring DTP/telehealth channel, specialty drugs needing hub + pharmacy integration, brands needing omnichannel HCP/patient engagement

Sources

• EVERSANA Patient Services General Capabilities Deck, 2024 (49 pages)
• ConnectiveRx IC #1 Memo, October 31, 2022 (precedent transactions reference: InTouch Group acquired by EVERSANA for $975M / 21.3x EBITDA, Oct 2021)
• ConnectiveRx IC #2 Memo, November 7, 2022 (competitive landscape context)